Teva's US exclusive dealing theory fails as matter of law, Corcept says
MLex Summary: Corcept Therapeutics moved for summary judgment on Teva Pharmaceuticals’ antitrust claims. In its motion, Corcept argued that "[t]hrough several rounds of motion to dismiss briefing, Teva convinced the court...To view the full article, register now.
Already a subscriber? Click here to view full article